Previous Article | Next Article ![]()
Clinical and Diagnostic Laboratory Immunology, September 2001, p. 943-948, Vol. 8, No. 5
Experimental Immunology
Branch,1 HIV and AIDS Malignancy
Branch,2 and Biostatistics and Data
Management Section, National Cancer Institute,3
National Institutes of Health, Bethesda, Maryland
Received 26 January 2001/Returned for modification 9 March
2001/Accepted 13 June 2001
The present study analyzes the effect of highly active
antiretroviral therapy (HAART) on restoration of cellular immunity in
human immunodeficiency virus (HIV)-infected children over a 24-week
period following initiation of HAART with ritonavir, nevirapine, and
stavudine. The immunological parameters evaluated at four time points
(at enrollment and at 4, 12, and 24 weeks of therapy) included cytokine
production by monocytes as well as T-cell proliferation in
response to mitogen, alloantigen, and recall antigens including HIV
type 1 envelope peptides. Circulating levels of interleukin-16 (IL-16)
were measured, in addition to CD4+ T-cell counts, plasma
HIV RNA levels, and the delayed-type hypersensitivity (DTH) response.
At enrollment the children exhibited defects in several immune
parameters measured. Therapy increased CD4+ T-cell counts
and decreased viral loads significantly. By contrast, the only
immunological parameter that was significantly increased was IL-12
p70 production by monocytes; the DTH response to Candida albicans also showed a strong increase in patients becoming
positive. In conclusion, these results demonstrate that HAART in
HIV-infected children affects the dynamics of HIV replication and the
CD4+ T-cell count over 24 weeks, similar to the
pattern seen in HIV-infected adults. Furthermore, these data
indicate improvement in antigen-presenting cell immunological function
in HIV-infected children induced by HAART.
1071-412X/01/$04.00+0 DOI: 10.1128/CDLI.8.5.943-948.2001
Highly Active Antiretroviral Therapy in Human Immunodeficiency
Virus Type 1-Infected Children: Analysis of Cellular Immune
Responses
*
Corresponding author. Present address: University of
Tampere, Institute of Medical Technology, Lenkkeilijankatu 6, 33101 Tampere, Finland. Phone: 358 3 2157755. Fax: 358 3 2157332. E-mail:
ltvebl{at}uta.fi.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»